<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/19/valuengine-upgrades-nanthealth-nasdaqnh-to-hold.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-19T22:24:41+00:00"/>
    <meta property="og:title" content="ValuEngine Upgrades NantHealth (NASDAQ:NH) to Hold"/>
    <meta property="og:description" content="NantHealth (NASDAQ:NH) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, ValuEngine reports. Several other brokerages also recently issued reports on NH. Zacks Investment Research downgraded shares of NantHealth from a “buy” rating to a “hold” rating in a research […]"/>
  </head>
  <body>
    <article>
      <h1>ValuEngine Upgrades NantHealth (NASDAQ:NH) to Hold</h1>
      <address><time datetime="2019-11-19T22:24:41+00:00">19 Nov 2019, 22:24</time> by <a rel="author" href="https://www.thecerbatgem.com/author/amy" target="_blank">Amy Steele</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/nanthealth-llc-logo.png"/>
      </figure>
      <p>NantHealth (NASDAQ:NH) was upgraded by stock analysts at <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=NH">ValuEngine</a> from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, <a href="https://www.valuengine.com/">ValuEngine</a> reports.</p>
      <p>Several other brokerages also recently issued reports on NH. <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> downgraded shares of NantHealth from a “buy” rating to a “hold” rating in a research note on Thursday, August 15th. Cowen set a $1.00 price objective on shares of NantHealth and gave the stock a “buy” rating in a research note on Monday, August 26th.</p>
      <p><a href="https://www.marketbeat.com/stocks/NASDAQ/NH/price-target/">NASDAQ NH</a> traded up $0.10 during trading on Tuesday, hitting $1.03. The stock had a trading volume of 387,400 shares, compared to its average volume of 188,987. The stock has a market capitalization of $96.24 million, a price-to-earnings ratio of -0.59 and a beta of 1.21. NantHealth has a one year low of $0.45 and a one year high of $1.96. The stock has a 50 day simple moving average of $0.74 and a 200 day simple moving average of $0.63.</p>
      <p>NantHealth (NASDAQ:NH) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.08). The firm had revenue of $22.36 million during the quarter, compared to the consensus estimate of $23.40 million. NantHealth had a negative return on equity of 10,106.10% and a negative net margin of 105.82%. On average, sell-side analysts expect that NantHealth will post -0.46 EPS for the current fiscal year.</p>
      <p>A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC lifted its stake in NantHealth by 778.8% in the third quarter. Tower Research Capital LLC TRC now owns 45,988 shares of the company’s stock worth $33,000 after purchasing an additional 40,755 shares during the last quarter. Paloma Partners Management Co lifted its stake in NantHealth by 436.1% in the second quarter. Paloma Partners Management Co now owns 91,100 shares of the company’s stock worth $48,000 after purchasing an additional 74,108 shares during the last quarter. Finally, Miracle Mile Advisors LLC lifted its stake in NantHealth by 154.2% in the second quarter. Miracle Mile Advisors LLC now owns 75,000 shares of the company’s stock worth $39,000 after purchasing an additional 45,500 shares during the last quarter. 3.27% of the stock is owned by institutional investors and hedge funds.</p>
      <p>
        <b>About NantHealth</b>
      </p>
      <p>NantHealth, Inc, together with its subsidiaries, operates as a healthcare technology company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care. It develops NantHealth solutions, including molecular profiling solutions, software, and hardware systems infrastructure, which integrates patient data management, bioinformatics, and molecular medicine to enable value-based care and evidence-based clinical practice.</p>
      <p>Featured Story: <a href="https://www.marketbeat.com/financial-terms/growth-stocks-what-they-are/">Growth Stocks</a></p>
      <p>To view ValuEngine’s full report, visit <a href="https://www.valuengine.com/rep/order_report?pid=64&amp;srchfor=NH">ValuEngine’s official website</a>.</p>
    </article>
  </body>
</html>